Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company''s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest shares articles
Nasdaq 100: Trading US CPI
Futures up on Nvidia’s China sales resumption of AI chips, but the next test is US pricing data.
06:29, 15 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:58, 14 July 2025
Top 5 biggest short squeezes
Explore five iconic short squeeze cases like GameStop & Tesla. Learn how positioning, sentiment & timing drive dramatic market moves.
15:09, 14 July 2025
Nvidia stock forecast: Third-party price target
Discover third-party Nvidia stock forecast predictions for 2025-2030 and beyond, with analyst targets, historical prices, and trading strategies.
15:41, 11 July 2025
Ratings and Reviews
Ratings and Reviews
